Editas Medicine Inc. – Material Contracts Watch

from 10-K 2 pages Editas Medicine Director Compensation

from 10-K 2 pages Amy Parison Dear Amy, Congratulations on Your Appointment to Svp, Chief Financial Officer. I Am Confident in This Appointment and Your Ability to Rise to the Needs of the Role. Your Track Record of Financial Decision-Making, Accounting Acumen, and Team Leadership Abilities Make You the Natural Choice to Succeed Erick Lucera. in Addition, Your Intelligence and Robust Enterprise View Position You for Success. I Look Forward to Seeing Your Continued Growth and Impact on Editas! Below Are Details of Your Promotion and New 2025 Compensation. Base Salary Information Current Base Salary($) $340,000 Increase(%) 22.1% Proposed New Salary($) $415,000 2025 Target Bonus(%) 40% 2025 Total Target Cash ($) $581,000 Salary Effective Date March 28th , 2025 Equity Grant Information Annual Grant Stock Options* 34,672 Grant Date April 8th , 2025 * the Strike Price Will Be Equal to the Closing Price of the Company's Common Stock on the NASDAQ Global Select Market on the Grant Date. Your Annual Grant Stock Options Will Vest Over 4 Years at a Rate of 2.0833% of the Original Number of Shares Per Month, Commencing One Month After the Grant Date of April 8th , 2025 Until Fully Vested on the Fourth Anniversary of the Grant Date. Please Indicate Your Acceptance of This Offer by Signing the Enclosed Copy of This Offer Letter and the Agreement via the Electronic Signature Tool, No Later Than Monday, March 24, 2025. Gilmore O'NEILL President and Chief Executive Officer the Foregoing Correctly Sets Forth the Terms of My Employment by the Company. I Am Not Relying on Any Other Representation, Except as Set Forth in This Offer Letter. Sincerely, /S/ Gilmore Oneill /S/ Amy Parison Signature 3/29/2025 Date

from 10-K 7 pages Material contract

from 8-K 14 pages Editas Medicine, Inc. Amended and Restated 2015 Stock Incentive Plan

from 10-K 53 pages Material contract

from 10-K 16 pages Material contract

from 10-Q 4 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Information of the Type That the Registrant Customarily and Actually Treats as Private or Confidential. Double Asterisks Denote Omissions. First Amendment to the Second Amended and Restated Collaboration and License Agreement

from 10-K 3 pages Omnibus Amendment

from 10-K 2 pages Editas Medicine Director Compensation

from 10-K 7 pages Editas Medicine, Inc. Inducement Restricted Stock Unit Agreement

from 10-K 9 pages Editas Medicine, Inc. Inducement Stock Option Agreement

from 10-K 6 pages Editas Medicine, Inc. Restricted Stock Unit Agreement

from 10-K 4 pages Restricted Stock Agreement 2015 Stock Incentive Plan

from 10-K 5 pages Editas Medicine, Inc. Nonstatutory Stock Option Agreement

from 10-K 5 pages Editas Medicine, Inc. Incentive Stock Option Agreement

from 8-K 12 pages Amended and Restated Severance Benefits Plan

from 10-Q 14 pages Material contract

from 10-Q 8 pages ​ July 2, 2023 ​ ​ Linda Burkly, PH.D. ​ ​ Re: Offer of Employment ​ ​ Dear Linda, ​ on Behalf of Editas Medicine, Inc. (The “Company”), I Am Pleased to Offer You Employment With the Company. the Purpose of This Letter (The “Offer Letter”) Is to Set Forth the Terms of Your Employment With the Company, Should You Accept Our Offer

from 10-Q 12 pages ​ via Hand Delivery May 11, 2023 (As Revised at Your Request on May 15, 2023) Michelle Robertson ​ Dear Michelle,

from 10-Q 8 pages ​ May 12, 2023 ​ Erick Lucera ​ Re: Offer of Employment ​ Dear Erick, ​ on Behalf of Editas Medicine, Inc. (The “Company”), I Am Pleased to Offer You Employment With the Company. the Purpose of This Letter (The “Offer Letter”) Is to Set Forth the Terms of Your Employment With the Company, Should You Accept Our Offer